Questions presented
SCOTUS records, cert granted 4 Nov 2022
- Section 112 of the Patent Act provides that a patent's "specification shall contain a written description of the invention, and of the manner and process of making and using it," sufficient "to enable any person skilled in the art * * * to make and use the" invention. 35 U.S.C. § 112(a). The requirement that the specification teach skilled artisans "to make and use" the invention is referred to as the "'enablement'" requirement. Markman v. Westview Instruments, Inc., 517 U.S. 370, 379 (1996). The questions presented are:
- Whether enablement is "a question of fact to be determined by the jury," Wood v. Underhill, 46 U.S. (5 How.) 1, 4 (1846), as this Court has held, or "a question of law that [the court] review[s] without deference," Pet. App. 6a, as the Federal Circuit holds.
- Whether enablement is governed by the statutory requirement that the specification teach those skilled in the art to "make and use" the claimed invention, 35 U.S.C. § 112, or whether it must instead enable those skilled in the art "to reach the full scope of claimed embodiments" without undue experimentation-i.e., to cumulatively identify and make all or nearly all embodiments of the invention without substantial "'time and effort,'" Pet.App. 14a (emphasis added).
Opinion summary
Etalia.ai summary of the majority opinion
The case involved patents on antibodies that help lower LDL cholesterol by binding to PCSK9 and blocking it from binding to LDL receptors. Amgen claimed two later patents that described an entire class of antibodies by function and identified 26 examples by amino acid sequence. Sanofi argued the claims were invalid because the patents did not enable skilled scientists to make and use the full scope of what was claimed. The Court, in an opinion by Justice Gorsuch, agreed and held that Amgen did not satisfy the Patent Act’s enablement requirement. The Court said a patent that claims an entire class must enable a person skilled in the art to make and use the whole class, not just a few examples. It concluded that Amgen’s “roadmap” and “conservative substitution” methods amounted to little more than trial and error and did not adequately teach the full breadth of the claimed antibodies. The judgment below was affirmed.
Opinion written by Justice Gorsuch
Decided 18 May 2023 · Official report
Oral argument transcript
Argued 27 Mar 2023